Trial Profile

A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mometasone (Primary)
Indications Eosinophilic oesophagitis
Focus Proof of concept; Therapeutic Use
Acronyms ACESO
Sponsors EsoCap AG

Most Recent Events

22 Apr 2025 According to an EsoCap AG media release, data from this trial will be presented at Digestive Disease Week (DDW) 2025, taking place May 3 to 6 in San Diego, USA.
22 Apr 2025 Results presented in the EsoCap AG media release.
17 Dec 2024 According to an EsoCap AG media release, results from this study published in the peer-reviewed medical journal Alimentary Pharmacology & Therapeutics.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com